普拉洛芬联合玻璃酸钠治疗老年糖尿病白内障术后干眼症的疗效观察

Effect of pranoprofen combined with sodium hyaluronate on xerophthalmia in senile diabetic patients after cataract surgery

  • 摘要: 目的 观察普拉洛芬联合玻璃老年酸钠治疗老年糖尿病白内障术后干眼症的临床疗效。 方法 将徐州第三人民医院眼科2016年1月- 2018年1月收治的120例老年糖尿病白内障术后干眼症患者作为研究对象,随机分为对照组、实验组(各60例)。对照组仅给予玻璃酸钠治疗(每次1滴,每日4次),实验组在玻璃酸钠治疗基础上加用普拉洛芬(每次1滴,每日4次)。1个月后通过泪膜破裂时间(tear break-up time,BUT)、泪液分泌实验(SchrmerⅠ)、角膜荧光染色评分评价临床疗效。 结果 治疗后,实验组BUT、SchrmerⅠ结果均高于对照组BUT:(11.07±1.66) s vs (7.50±1.02) s;SchrmerⅠ:(7.33±2.11) mm vs (5.03±0.82) mm,荧光染色评分分明显低于对照组(2.13±0.68 vs 4.22±0.67),差异均存在统计学意义(P< 0.05)。 结论 普拉洛芬联合玻璃酸钠治疗老年糖尿病白内障术后干眼症较单独应用玻璃酸钠临床疗效更为显著。

     

    Abstract: Objective To investigate the clinical effect of pranoprofen combined with sodium hyaluronate in treatment of xerophthalmia after diabetic cataract surgery. Methods One hundred and twenty patients with xerophthalmia after cataract surgery in Xuzhou Third People's Hospital from January 2016 to January 2018 were randomly divided into control group and experimental group (with 60 cases in each group). The control group was treated with sodium hyaluronate (1 drop, 4 times per day), and the experimental group was treated with pranoprofen (1 drop, 4 times per day) on the basis of sodium hyaluronate treatment. One month later, the clinical effect of the two groups was evaluated using tear fi lm rupture time (BUT), tear secretion test (SchrmerⅠ) and corneal fluorescent staining score. Results After treatment, BUT and SchrmerⅠ in the experimental group were significantly higher than those in the control group BUT, (11.07±1.66) s vs (7.50±1.02) s; SchrmerⅠ, (7.33±2.11) mm vs (5.03±0.82) mm, while the fluorescence staining score was significantly lower than that in the control group (2.13±0.68) vs (4.22±0.67) (all P< 0.05). Conclusion Compared with sodium hyaluronate alone, the clinical effect of praprofen combined with sodium hyaluronate in the treatment of xerophthalmia in senile diabetic patients after cataract surgery is more significant.

     

/

返回文章
返回